Printed From BioPortfolio.com

AstraZeneca’s Imfinzi fails to improve OS in head and neck cancer trial

04:46 EST 10 Dec 2018 | Pharmaceutical Business Review

The phase II Eagle trial is a randomized, open-label and multi-centre trial designed to assess Imfinzi monotherapy and Imfinzi in combination with anti-CTLA4 antibody tremelimumab against SoC chemotherapy

The post AstraZeneca’s Imfinzi fails to improve OS in head and neck cancer trial appeared first on Pharmaceutical Business review.

Original Article: AstraZeneca’s Imfinzi fails to improve OS in head and neck cancer trial

More From BioPortfolio on "AstraZeneca’s Imfinzi fails to improve OS in head and neck cancer trial"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

News Quicklinks

Search Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches